Kymriah CAR T Cell Therapy: The First CAR-T’s Legacy in 2026
Introduction: The Therapy That Started It All
On August 30, 2017, the U.S. Food and Drug Administration approved a treatment unlike anything that had come before. Kymriah (tisagenlecleucel) became the first chimeric antigen receptor T-cell (CAR-T) therapy and the first cell-based gene therapy ever approved in the United States. For oncologists, researchers, and families of children with aggressive blood cancers, the moment marked the arrival of a new era in medicine.
The human face of that breakthrough is Emily Whitehead. She was a young girl with relapsed leukemia who became the first pediatric patient to receive the experimental therapy in 2012. More than a decade later, she remains alive and well, and her story is still told whenever the origins of cellular immunotherapy come up.
By 2026, however, Kymriah no longer stands alone. Six broadly recognized CAR-T products hold FDA approval, and newer entrants continue to arrive. That raises a central question: what does it mean for a pioneering therapy to compete in a field it helped create?
This article traces the full arc of Kymriah CAR T cell therapy as the category-defining “first.” It covers the therapy’s origin story, the science behind it, the clinical trial setback that reshaped its competitive position, and where it stands today for patients and families evaluating their options.
The Origin Story: From Penn Lab to FDA Milestone
Kymriah began as an academic research program. In 2012, the University of Pennsylvania and Novartis formalized a collaboration to develop an investigational therapy then known as CTL019. The partnership paired Penn’s laboratory innovation with Novartis’s capacity for large-scale clinical development and commercialization.
The scientific architect behind the approach was Dr. Carl June, whose team at Penn spent years refining the concept of reprogramming a patient’s own immune cells to fight cancer. Their work drew on decades of immunology research, but CTL019 was among the first efforts to show that engineered T-cells could produce dramatic, lasting responses in patients who had exhausted conventional options.
Emily Whitehead’s treatment in 2012 became a defining moment. As the first pediatric patient enrolled in the experimental trial, she had relapsed acute lymphoblastic leukemia (ALL) and faced a grim prognosis. Her response to the therapy offered early, powerful evidence that the approach could work in children.
The concept itself was elegant. Many B-cell cancers carry a surface protein called CD19. By genetically engineering a patient’s T-cells to recognize CD19, researchers could turn the immune system into a targeted weapon against cancerous B-cells.
This represented a fundamentally new treatment modality. Chemotherapy works by broadly attacking rapidly dividing cells. Targeted small-molecule drugs block specific molecular pathways. CAR-T therapy differs from both: it is a living drug, built from a patient’s own cells, designed to expand and persist in the body after a single infusion.
A Historic First: The 2017 FDA Approval
The FDA’s initial approval covered patients up to 25 years of age with B-cell precursor ALL that was refractory to treatment or in second or later relapse. This population had very few remaining options.
The approval rested on the pivotal ELIANA trial, which enrolled 63 pediatric and young adult patients. According to Novartis’s original announcement, the trial showed an 83% overall remission rate within three months of infusion. For a population that previously had a five-year survival rate of less than 10%, the result was extraordinary.
The approval carried a dual distinction. Kymriah was:
- The first CAR-T cell therapy approved in the United States
- The first cell-based gene therapy approved in the United States
Long-term data have since reinforced the significance of those early results. Follow-up of ELIANA patients over five or more years, reported by Novartis and the Children’s Hospital of Philadelphia, shows a five-year relapse-free survival of roughly 44% and an overall remission rate of about 82%. For many of these patients, outcomes that once seemed impossible have held up over time. That durability is why Kymriah is often described as delivering “cure-level” outcomes for a subset of children and young adults.
Expanding the Reach: Additional Indications Over Time
Kymriah’s role grew beyond pediatric leukemia within a year of its first approval.
May 2018: Large B-cell lymphoma. The FDA approved Kymriah for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This indication included:
- Diffuse large B-cell lymphoma (DLBCL)
- High-grade B-cell lymphoma
- DLBCL arising from follicular lymphoma
With this approval, Kymriah became the only CAR-T therapy at the time approved for two distinct indications, spanning both a pediatric leukemia and an adult lymphoma.
May 2022: Follicular lymphoma. Kymriah gained a third U.S. indication for adult patients with relapsed or refractory follicular lymphoma after two or more lines of therapy. This expansion was based on Phase 2 data presented at the American Society of Clinical Oncology (ASCO) annual meeting in 2021.
Together, these approvals established Kymriah as a therapy with reach across both pediatric and adult hematologic malignancies. That breadth set it apart during the early years of the CAR-T era.
How Kymriah Works: The Science Behind the Therapy
The CAR-T process follows a series of carefully controlled steps:
- Collection. A patient’s T-cells are extracted from the blood through a process called leukapheresis.
- Engineering. The cells are sent to a manufacturing facility, where they are genetically modified to express a chimeric antigen receptor that targets CD19.
- Expansion. The engineered cells are grown until they reach a therapeutic dose.
- Reinfusion. The finished product is shipped back to the treatment center and infused into the patient, usually after a short course of lymphodepleting chemotherapy.
A key design feature is Kymriah’s costimulatory domain. This part of the CAR construct helps activate the T-cell once it binds its target. Kymriah uses a 4-1BB costimulatory domain, which it shares with Breyanzi. Yescarta uses a CD28 domain instead.
Comparative literature, including peer-reviewed overviews of approved CAR-T products, frequently cites this difference when discussing how the therapies behave in the body. The 4-1BB domain is generally associated with longer T-cell persistence and a different toxicity pattern. CD28-based constructs are often associated with faster, more intense expansion. Direct head-to-head comparisons remain limited, so these distinctions are best understood as general tendencies rather than definitive rankings.
Like all CAR-T therapies, Kymriah carries serious safety considerations. According to the FDA prescribing information, the boxed warnings include:
- Cytokine release syndrome (CRS): A systemic inflammatory response that can cause fever, low blood pressure, and organ dysfunction
- Neurological toxicities: Including confusion, speech difficulties, seizures, and other effects
Because of these risks, CAR-T therapies are given at specialized treatment centers with teams experienced in recognizing and managing these complications.
The Turning Point: How Kymriah Lost Ground in Lymphoma
For CAR-T developers, moving into earlier lines of treatment was a major strategic goal. In DLBCL, the standard second-line approach involved high-dose chemotherapy followed by autologous stem cell transplant. A CAR-T therapy that could outperform that standard in second-line patients would reach a much larger population and change treatment practice.
In December 2021, three major trials delivered results in this setting, and the outcomes diverged sharply:
| Trial | Therapy | Manufacturer | Outcome in Second-Line LBCL |
|---|---|---|---|
| ZUMA-7 | Yescarta | Gilead/Kite | Succeeded vs. standard of care |
| TRANSFORM | Breyanzi | Bristol Myers Squibb | Succeeded vs. standard of care |
| BELINDA | Kymriah | Novartis | Did not outperform standard of care |
As BioPharma Dive reported at the time, analysts pointed to differences in trial design as possible contributors to the divergent results. These included how patients were managed while awaiting cell manufacturing and the use of bridging therapy. Whatever the reasons, the consequence was clear.
Yescarta and Breyanzi went on to gain second-line approval for large B-cell lymphoma. Kymriah remains restricted in the U.S. to use after two or more prior lines of therapy.
This was the pivotal business and scientific moment that reshaped the CAR-T hierarchy. The first therapy to reach the market found itself locked out of the earlier treatment setting, where competitors now had room to grow.
Kymriah in 2026: Manufacturing, Regulation, and Commercial Reality
Manufacturing Challenges
Autologous CAR-T manufacturing is complex because every dose is made from an individual patient’s cells. Novartis has faced persistent challenges with Kymriah, including:
- Product variability between batches
- Out-of-specification batches that did not meet release criteria
- Shipment failures affecting delivery timelines
The company responded by expanding manufacturing capacity in Stein, Switzerland, and by acquiring CellforCure in France to add production capability. Novartis has also invested in next-generation platforms such as T-Charge, designed to shorten manufacturing time and improve the quality of the cells, as part of its strategy to defend its position in the market.
Regulatory Evolution
In June 2024, the FDA approved updates to Kymriah’s prescribing information, including removal of the Risk Evaluation and Mitigation Strategy (REMS) requirement. The REMS program had required certified sites and specific training protocols. Its removal reflected the agency’s growing confidence that treatment centers had developed the experience to manage CAR-T safety risks effectively. Boxed warnings and close monitoring requirements remain in place.
Intellectual Property
In Europe, Novartis’s patent covering Kymriah (EP3214091B1) was withdrawn after opposition from the NGOs Doctors of the World and Public Eye. Novartis stated that the patent was not critical to Kymriah’s continued commercialization.
Commercial Standing
According to Novartis’s recent financial disclosures, including its FY2025 filing with the SEC, Kymriah is now a smaller and declining revenue line compared with its peak. Sales have fallen year over year, reflecting displacement by Yescarta and Breyanzi in lymphoma. Kymriah retains relatively stronger footing in pediatric and young adult ALL and in follicular lymphoma uptake outside the United States.
Where Kymriah Stands in the 2026 CAR-T Landscape
The CAR-T field now includes six broadly recognized FDA-approved commercial products:
CD19-targeted therapies:
- Kymriah (tisagenlecleucel), Novartis
- Yescarta (axicabtagene ciloleucel), Gilead/Kite
- Tecartus (brexucabtagene autoleucel), Gilead/Kite
- Breyanzi (lisocabtagene maraleucel), Bristol Myers Squibb
BCMA-targeted therapies (for multiple myeloma):
- Abecma (idecabtagene vicleucel), Bristol Myers Squibb
- Carvykti (ciltacabtagene autoleucel), Johnson & Johnson/Legend Biotech
Among these, Kymriah holds a unique distinction: the longest real-world safety record of any approved CAR-T therapy. Clinicians have been able to observe outcomes over many years in actual practice.
Areas of relative strength:
- Pediatric and young adult B-cell ALL, where Kymriah has the deepest long-term evidence base
- Follicular lymphoma, particularly in markets outside the U.S.
Areas of displacement risk:
- Adult DLBCL, where Yescarta and Breyanzi now dominate earlier-line use
The field keeps getting more crowded. Newer approvals, such as Aucatzyl (obecabtagene autoleucel) for adult B-cell ALL, have extended CAR-T options in leukemia. Products approved in China, including Carteyva and Fucaso, point to growing global competition. Developers are also pursuing allogeneic, “off-the-shelf” CAR-T candidates made from donor cells, which could eventually remove the need for patient-specific manufacturing.
In this environment, Kymriah serves two roles at once. It is the historical benchmark against which newer therapies are measured, and it is a still-relevant treatment option within specific clinical niches.
What This Means for Patients Evaluating Treatment Options
For patients and families, the most important point is that CAR-T choice depends on specific diagnosis, prior treatment history, and eligibility criteria, not brand recognition. Each product carries its own approved indications, and those differences matter.
- Pediatric and young adult ALL: Kymriah remains a well-established option with more than a decade of real-world outcomes data behind it.
- Adult DLBCL in the second-line setting: Yescarta or Breyanzi may be more applicable, since they hold approval for that stage of treatment and Kymriah does not.
- Adult DLBCL after two or more prior therapies, and follicular lymphoma: Several products, including Kymriah, may be options depending on individual circumstances.
Because indications and eligibility vary by product, patients should discuss all approved treatment options with a hematologist-oncologist and an experienced CAR-T treatment center. Factors such as overall health, disease characteristics, manufacturing timelines, and access to specialized care all influence the decision.
Cost is also a common concern. Analyses by the Institute for Clinical and Economic Review (ICER) have found that Kymriah’s cost-effectiveness for its approved indications falls within commonly cited quality-adjusted life year (QALY) thresholds. Actual costs to patients depend heavily on insurance coverage and treatment setting, so these questions are best addressed with the treatment center’s financial counseling team.
Kymriah’s Broader Legacy for the CAR-T Field
Kymriah’s 2017 approval did more than introduce a single product. It opened the regulatory and clinical pathway for an entire category of cell-based gene therapies. Every CAR-T approval since has built on the precedent it set.
Its launch also shaped early market dynamics. Kymriah entered the market with a very limited launch-year patient population of about 135 patients, reflecting the narrow initial indication and the specialized manufacturing process required. Those conditions set early expectations for how payers, hospitals, and manufacturers would approach these therapies, and later CAR-T products had to work within that framework.
Its manufacturing difficulties carried lessons as well. The challenges Novartis encountered with variability, specification failures, and logistics helped define the process improvements that competitors and next-generation platforms have since adopted.
Regardless of its current commercial position, Kymriah provided the clinical and scientific proof of concept that made subsequent approvals possible. It showed that engineered T-cells could be manufactured, delivered, and approved at scale.
Emily Whitehead’s story remains the most enduring symbol of that achievement. A child who received an experimental therapy in 2012 grew up alongside the field her treatment helped launch, and she represents what CAR-T medicine has accomplished for thousands of patients since.
Conclusion: A Pioneer’s Place in a Maturing Field
Kymriah holds a dual identity in 2026. It is a category-defining historical milestone, and it is a therapy navigating a more competitive, specialized role.
Its trajectory includes several key inflection points:
- The 2017 approval as the first CAR-T and first cell-based gene therapy in the U.S.
- Indication expansions into large B-cell lymphoma in 2018 and follicular lymphoma in 2022
- The BELINDA trial setback in 2021, which kept it out of second-line DLBCL
- Regulatory and manufacturing developments from 2024 through 2026, including REMS removal and investment in next-generation platforms
Kymriah’s legacy is secure even as its market share changes. Durable long-term outcomes in pediatric and young adult ALL, along with the longest real-world safety record in the field, keep it clinically meaningful. And the CAR-T field built on its foundation continues to expand with new products, new targets, and new manufacturing approaches.
Next Steps for Patients and Caregivers
Anyone considering CAR-T therapy should take these steps:
- Consult a qualified specialist. A hematologist-oncologist can evaluate eligibility for any CAR-T therapy, including Kymriah, based on diagnosis and treatment history.
- Review official prescribing information. The FDA prescribing information for each product outlines approved indications, safety warnings, and administration requirements.
- Connect with an experienced treatment center. Centers with established CAR-T programs can explain logistics, manufacturing timelines, monitoring requirements, and financial counseling resources.
- Stay informed. New therapies, expanded indications, and manufacturing advances continue to emerge, and the options available today may broaden in the coming years.
General information can help patients and caregivers ask better questions, but it cannot replace personalized medical guidance. Treatment decisions should always be made with a care team that understands the individual patient’s situation.
